Penetrating perineal trauma is an unusual urologic injury. Even less common is a delayed presentation. Herein we present the case of a patient with delayed development of a corporal cutaneous fistula 3 months following perineal trauma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2019.04.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Smoking status is a negative predictor of six-month cutaneous lupus activity trends: A prospective cohort study.
J Am Acad Dermatol
December 2024
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:
Subtype and Racial Erythema Variation for Cutaneous Lupus Trials.
JAMA Dermatol
January 2025
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.
Article Synopsis
- Regulatory guidance on disease outcome measures is crucial for improving clinical trials for cutaneous lupus erythematosus (CLE) and increasing participant diversity.
- A study of 377 CLE patients analyzed erythema variations across different subtypes and racial/ethnic groups to see how these differences impact eligibility for trials.
- Results showed significant erythema differences among CLE subtypes and among racial/ethnic groups, particularly with SCLE and hypertrophic CCLE being primarily classified as red.
Chaetotaxy of the fourth larval stage of Pintomyia longiflocosa, a primary vector of cutaneous leishmaniasis in Colombia.
Biomedica
November 2024
Grupo de Entomología, Instituto Nacional de Salud, Bogotá, D. C., Colombia.
Introduction: Pintomyia (Pifanomyia) longiflocosa is an endemic species from Colombia, found between the central and eastern Andes, and reported as one of the primary vectors of cutaneous leishmaniasis in coffee-growing zones of the country. This species is classified in the Townsendi series and can only be identified by the morphology of the male adults.
Objective: To determine the potential use of the fourth larval stage of the vector Pi.
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.
JID Innov
January 2025
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Article Synopsis
- - Dermatomyositis (DM) is a rare autoimmune disease affecting the skin and is often difficult to treat, with standard medications sometimes ineffective; lenabasum, a selective cannabinoid receptor 2 agonist, shows promise in managing these skin-related symptoms.
- - In a study involving a 3-year open-label extension of a Phase 2 trial with 20 patients resistant to traditional treatments, researchers assessed the long-term effectiveness and recurrence of DM symptoms while on lenabasum.
- - Results indicated significant improvements in skin disease activity and stability, with 58.3% of patients maintaining stable conditions and a notable reduction in flare-ups, suggesting lenabasum as a viable treatment for difficult-to-manage DM cases. *
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!